Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Int J Mol Sci. 2021 May 23;22(11):5497. doi: 10.3390/ijms22115497.
More than 250 million people are living with chronic hepatitis B despite the availability of highly effective vaccines and oral antivirals. Although innate and adaptive immune cells play crucial roles in controlling hepatitis B virus (HBV) infection, they are also accountable for inflammation and subsequently cause liver pathologies. During the initial phase of HBV infection, innate immunity is triggered leading to antiviral cytokines production, followed by activation and intrahepatic recruitment of the adaptive immune system resulting in successful virus elimination. In chronic HBV infection, significant alterations in both innate and adaptive immunity including expansion of regulatory cells, overexpression of co-inhibitory receptors, presence of abundant inflammatory mediators, and modifications in immune cell derived exosome release and function occurs, which overpower antiviral response leading to persistent viral infection and subsequent immune pathologies associated with disease progression towards fibrosis, cirrhosis, and hepatocellular carcinoma. In this review, we discuss the current knowledge of innate and adaptive immune cells transformations that are associated with immunopathogenesis and disease outcome in CHB patients.
尽管有高效的疫苗和口服抗病毒药物,仍有超过 2.5 亿人患有慢性乙型肝炎。尽管先天和适应性免疫细胞在控制乙型肝炎病毒 (HBV) 感染方面发挥着关键作用,但它们也与炎症有关,随后导致肝脏病变。在 HBV 感染的初始阶段,先天免疫被触发,导致抗病毒细胞因子的产生,随后激活和肝内适应性免疫系统的募集,导致成功清除病毒。在慢性 HBV 感染中,先天和适应性免疫都发生了显著改变,包括调节性细胞的扩增、共抑制受体的过度表达、丰富的炎症介质的存在,以及免疫细胞来源的外泌体释放和功能的改变,这些改变削弱了抗病毒反应,导致持续的病毒感染和随后的免疫病理学与疾病进展相关,包括纤维化、肝硬化和肝细胞癌。在这篇综述中,我们讨论了与 CHB 患者免疫发病机制和疾病结局相关的先天和适应性免疫细胞转化的最新知识。